Every S-3 that Opus Genetics, Inc. (IRD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow IRD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRD filings page.
Opus Genetics, Inc. is registering a mixed "shelf" offering of up to $300,000,000 of common stock, preferred stock, debt securities, warrants and units, plus up to 34,449,749 shares of common stock issuable upon exercise of outstanding warrants and pre-funded warrants. A concurrent at-the-market program allows sales of up to $125,000,000 of common stock through Leerink Partners and Cantor Fitzgerald. As of June 30, 2026, 82,647,946 common shares were outstanding, with substantial additional shares reserved under options, warrants, pre-funded warrants and convertible notes. Net proceeds are intended for working capital and general corporate purposes, including research and development of its gene therapy pipeline for inherited retinal diseases and other ophthalmic disorders.
Opus Genetics, Inc. registers up to 2,678,570 shares of Common Stock for resale by selling stockholders.
The shares consist of 1,116,070 Purchased Shares issued under a Stock Purchase and Conversion Agreement and up to 1,562,500 Conversion Shares issuable upon conversion of Notes under a Note Purchase Agreement, with a Conversion Price of $6.72 per share. The company will not receive proceeds from resales; the registration satisfies a contractual covenant and permits the selling stockholders to sell on market or by private transactions. Shares outstanding were 82,565,835 as of May 31, 2026; last reported sale price was $4.12 on June 1, 2026.
Opus Genetics, Inc. is registering for resale up to 7,374,632 shares of Common Stock issuable upon conversion of 7,374,632 shares of Series B Non‑Voting Convertible Preferred Stock. The Private Placement closed on February 18, 2026 and the Company will not receive proceeds from resale; proceeds will be received by the selling stockholders. Shares outstanding were 71,402,472 as of March 31, 2026. The registration satisfies covenants in a registration rights agreement entered into on February 18, 2026.
Opus Genetics, Inc. is registering up to 7,374,632 shares of Common Stock for resale by the selling stockholders.
Those shares are issuable upon conversion of 7,374,632 shares of Series B Non‑Voting Convertible Preferred Stock and will be convertible following stockholder approval of an increase in authorized Common Stock and subject to each holder’s beneficial ownership limits.
The registration is a resale registration for the selling stockholders; the Company will not receive proceeds from resale. Shares outstanding were 71,149,045 as of March 5, 2026.